<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1351">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01735500</url>
  </required_header>
  <id_info>
    <org_study_id>hsTnT Elective CAG</org_study_id>
    <nct_id>NCT01735500</nct_id>
  </id_info>
  <brief_title>hsTnT After Elective Coronary Angiography</brief_title>
  <official_title>Rise of hscTnT After Elective Coronary Angiography Without Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <authority>Germany: University Hospital Heidelberg</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective Study, aiming to understand and analyse the key role of the novel High
      Sensitivity Troponin T (hsTnT) within a group of patients undergoing an uncomplicated
      coronary angiography without receiving any additional intervention. The peri-procedural
      elevation of the hsTnT indicates some other factors being responsible for the elevation of
      the hsTnT in absence of an acute coronary syndrome, such as physiological components or
      micro-injuries. A one year follow-up has been collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Up to 12 months after procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">545</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CAG without PCI</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CAG with PCI</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with stable or unknown CAD undergoing CAG with/or without PCI.
        Patients receiving additional examination, such as biopsy, Ablation or any other procedure
        that could lead to myocardial injury resulting in elevation of the cardiac Troponin are
        being excluded, as well as Patients with acute coronary syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Stable or unknown CAD

        Exclusion Criteria:

        - Acute Coronary Syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangelos Giannitsis, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University Hospital of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology - University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Haitham Abu Sharar</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Prei-procedural</keyword>
  <keyword>Elevation</keyword>
  <keyword>cardia Troponin T</keyword>
  <keyword>in stable</keyword>
  <keyword>unknown</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
